Statins and bone turnover

European Journal of Clinical Investigation

Volumn 32, Issue 8, 2002, Pages 543-544

  Lips, P ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CHOLESTEROL; ESTROGEN; GERANYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVALONIC ACID; NERIDRONIC ACID; NITROGEN; PARATHYROID HORMONE; STATIN;

AGE; BODY HEIGHT; BODY WEIGHT; BONE MASS; BONE TURNOVER; CELL MEMBRANE; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); CROSS REACTION; DRUG EFFECT; DRUG METABOLISM; FRAGILITY FRACTURE; HORMONE BLOOD LEVEL; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; INCIDENCE; INTESTINE ABSORPTION; METABOLISM; MORTALITY; NOTE; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED KINGDOM;

BIOLOGICAL MARKERS; BONE REMODELING; CASE-CONTROL STUDIES; DIPHOSPHONATES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; OSTEOPOROSIS;

EID: 0037002814     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2002.01025.x     Document Type: Note

References (14)

1. WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Treatment Report Series 843, World Health Organization, Geneva.; pp. 1-129. 1994.
2. Von der Recke P, Hansen MA, Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 1999;106:273-8.
3. Van Beek E, Löwik C, van der Pluijm G, Papapoulos S. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 1999;14:722-9.
4. Cummings SR, Bauer DC. Do statins prevent both cardiovascular disease and fracture? JAMA 2000;283:3255-7.
5. Adami S, Braga V, Guidi G, Gatti D, Gerardi D, Fracassi E. Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res 2000;15:599-604.
6. Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone mineral density in postmenopausal women. Lancet 2000;355:2218-19.
7. Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000;283:3211-16.
8. Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG et al. Inhibitors of hydroxymethylglutarylcoenzyme A reductase and risk of fracture among older women. Lancet 2000;355:2185-8.
9. Van Staa TP, Wegman S, De Vries F, Leufkens B, Cooper C. Use of statins and risk of fractures. JAMA 2001;285:1850-5.
10. Rejnmark L, Buus NH, Vestergaard P, Andreasen F, Larsen ML, Mosekilde L. Statins decrease bone turnover in postmenopausal women: a cross-sectional study. Eur J Clin Invest 2002;32:581-9.
11. Hennessy S, Strom BL. Statins and fracture risk. JAMA 2001;285:1888-9.
12. Mundy GR. Statins and their potential for osteoporosis. Bone 2001;29:495-7.
13. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286:1946-9.
14. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7.